YP 001

Drug Profile

YP 001

Alternative Names: Sabarep; Skin protease inhibitor YP001 - York Pharma; YP-001

Latest Information Update: 04 Apr 2011

Price : $50

At a glance

  • Originator York Pharma
  • Class Skin disorder therapies
  • Mechanism of Action Peptide hydrolase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Atopic dermatitis; Contact dermatitis

Most Recent Events

  • 15 Mar 2016 Biomarkers information updated
  • 13 Dec 2005 Phase-II clinical trials in Atopic dermatitis in United Kingdom (Topical)
  • 13 Dec 2005 Phase-II clinical trials in Contact dermatitis in United Kingdom (Topical)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top